Medical Device

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company") today announced that D. Robert Hale has resigned from his role as an independent director of the Company's Board of Directors ("Board") to focus on other business obligations related to his firm, ValueAct Capital ("ValueAct"), a shareholder of the Company.

"Rob has been a valued member of our Board since 2015, including formerly serving as our Chair of the Finance and Transactions Committee and as a member of the Talent and Compensation Committee, and most recently serving on the Special Transaction Committee. I would like to express my gratitude to ValueAct and to Rob for his numerous contributions, particularly as we have continued to transform Bausch Health," said Joseph C. Papa , chairman and CEO, Bausch Health . "As we continue to work to execute the spinoff of Bausch + Lomb and create two attractive businesses to unlock value, we are focused on forming two strong Boards with diverse representation and perspectives to ensure we represent the customers, patients and shareholders we serve around the world."

The Company and entire Board would like to thank Mr. Hale for his services and contributions and wish him well in his future endeavors.

"It has been a privilege to serve on the Bausch Health Board under Joe's leadership as he and the executive team transformed the Company in line with a mission to improve people's lives with the Company's health care products. With my increasing professional responsibilities outside of Bausch Health, including joining the board of a second company headquartered in Japan last week, and considering my capable colleagues on the Board representing all of Bausch Health's shareholders, I am resigning my seat," said D. Robert Hale .

"I fully support the Company's strategy to separate the global eye health business, its efforts to accelerate this strategy, and the ongoing leadership selection process. ValueAct remains an engaged and supportive shareholder. We are excited for what's ahead," Mr. Hale continued.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 856-3855

(908) 927-1198

(877) 281-6642 (toll free)


Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/bausch-health-announces-d-robert-hale-has-resigned-from-its-board-of-directors-301316127.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals

  • Two industry leaders join forces to empower people living with diabetes by providing information and insights to improve weight loss, glucose control and overall health
  • Collaboration will create a seamless, integrated experience between Abbott's world-leading continuous glucose monitoring device 1 and WeightWatchers' number one doctor-recommended weight loss program 2 to help individuals better understand and manage their diabetes and weight

Abbott (NYSE: ABT) and WW International, Inc. ("WeightWatchers" or "WW") today announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight. The companies are working together to integrate WeightWatchers' diabetes-tailored weight management program with Abbott's portfolio of FreeStyle Libre ® products to create a seamless mobile experience that will give people living with diabetes the information and insights needed to make healthy adjustments to their diet, improve their glucose levels, and, ultimately, gain more control of their health.

Maintaining a healthy body weight and having proper nutrition are critical to living well with diabetes. 3 Yet, for many people living with diabetes, determining what to eat and following a meal plan is the most challenging part of diabetes management. 4 Through this partnership, participants can receive glucose insights from Abbott's FreeStyle Libre sensor-based technology that show the impact of food choices, alongside the empirically validated 5 WeightWatchers' diabetes-tailored nutritional guidance to help them achieve their healthier living goals.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Second Quarter 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2022 financial results on Thursday, August 11, 2022 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, August 11, 2022

Time : 8:30 a.m. ET

Telephone : Toll Free: 1-855-669-9657 or International 1-412-317-0790

Webcast : www.gud- knight .com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

Replay : An archived replay will be available for 30 days at www.gud-knight.com .


________________________________________
About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET. A copy of the investor presentation will be available at www.gud-knight.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution for Real-Time Cryo-EM Data Analysis

New Embedded CryoSPARC Live software to be made available by Structura and Thermo Fisher and designed to integrate with Thermo Fisher technology

Thermo Fisher Scientific Inc., the world leader in serving science, and Structura Biotechnology Inc., a leading provider of cryo-EM data analysis software, today announced a collaboration to make available a new single particle analysis software solution, a version of Structura's CryoSPARC Live, that is designed to integrate with Thermo Fisher's Smart EPU software and cryo-transmission electron microscope (cryo-TEM) technology. The new solution, Embedded CryoSPARC Live , will be offered as a subscription.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Viemed Healthcare Announces Second Quarter 2022 Financial Results

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and six months ended June 30, 2022.

Operational highlights (all dollar amounts are USD):

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Wednesday, September 7 th . Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).

This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×